These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 22693730)

  • 1. [Pathomorphologic patient selection for systemic therapy].
    Olszewski WP; Chmielik E; Ryś J
    Pol J Pathol; 2011 Dec; 62(4 Suppl 4):s28-33. PubMed ID: 22693730
    [No Abstract]   [Full Text] [Related]  

  • 2. Ductal type signet ring cell carcinoma of breast with growth pattern of pure mucinous carcinoma.
    Leung KM; Yeoh GP; Chan JK; Cheung PS; Chan KW
    Pathology; 2011 Apr; 43(3):282-4. PubMed ID: 21436644
    [No Abstract]   [Full Text] [Related]  

  • 3. Is breast tumor progression really linear?
    Polyak K
    Clin Cancer Res; 2008 Jan; 14(2):339-41. PubMed ID: 18223205
    [No Abstract]   [Full Text] [Related]  

  • 4. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer immunohistochemical features in young women with BRCA 1/2 mutations.
    Zakhartseva LM; Gorovenko NG; Podolskaya SV; Anikusko NF; Lobanova OE; Pekur KA; Kropelnytskyi VA; Shurygina OV
    Exp Oncol; 2009 Sep; 31(3):174-8. PubMed ID: 19877382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.
    Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Aishima S; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 Apr; 19(4):1145-52. PubMed ID: 21984487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer.
    McCarthy NJ; Yang X; Linnoila IR; Merino MJ; Hewitt SM; Parr AL; Paik S; Steinberg SM; Hartmann DP; Mourali N; Levine PH; Swain SM
    Clin Cancer Res; 2002 Dec; 8(12):3857-62. PubMed ID: 12473600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Among triple-negative breast cancers, HER2(0) breast cancer shows a strong tendency to be basal-like compared with HER2(1+) breast cancer: preliminary results.
    Nakagawa M; Bando Y; Nagao T; Takai C; Ohnishi T; Honda J; Moriya T; Izumi K; Takahashi M; Tangoku A; Sasa M
    Breast Cancer; 2012 Jan; 19(1):54-9. PubMed ID: 21465226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer.
    Ivkovic-Kapicl T; Knezevic-Usaj S; Djilas-Ivanovic D; Panjkovic M
    In Vivo; 2007; 21(4):673-8. PubMed ID: 17708365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A proposed anatomical explanation for perineural spread of breast adenocarcinoma to the brachial plexus.
    Hébert-Blouin MN; Amrami KK; Loukas M; Spinner RJ
    Clin Anat; 2011 Jan; 24(1):101-5. PubMed ID: 21154646
    [No Abstract]   [Full Text] [Related]  

  • 12. HER-2 in breast cancer: a puzzle's piece!
    Arena V; Pennacchia I; Vecchio FM; Carbone A
    Int J Surg Pathol; 2012 Oct; 20(5):483. PubMed ID: 22415056
    [No Abstract]   [Full Text] [Related]  

  • 13. Basal cytokeratin expression in relation to biological factors in breast cancer.
    Kuroda H; Ishida F; Nakai M; Ohnisi K; Itoyama S
    Hum Pathol; 2008 Dec; 39(12):1744-50. PubMed ID: 18755493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
    Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
    Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Basal subtype of breast cancer--a unit of specific characteristics of immunophenotyping?].
    Niemiec J; Ryś J
    Pol J Pathol; 2011 Dec; 62(4 Suppl 4):s36-44. PubMed ID: 22693732
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II trial of preoperative chemotherapy for breast cancer: Japan Breast Cancer Research Network (JBCRN)-02 trial.
    Iwase S; Yamamoto D; Kuroda Y; Kawaguchi T; Kitamura K; Odagiri H; Teramoto S; Akazawa K; Nagumo Y
    Anticancer Res; 2011 Apr; 31(4):1483-7. PubMed ID: 21508407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer.
    Warm M; Kates R; Mallmann P; Dick M; Nawroth F; Harbeck N; Paepke S; Thomas A
    Anticancer Res; 2007; 27(2):1031-8. PubMed ID: 17465239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index.
    Miglietta L; Vanella P; Canobbio L; Parodi MA; Guglielmini P; Boccardo F
    Anticancer Res; 2009 May; 29(5):1621-5. PubMed ID: 19443376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Notch-1 and Notch-4 biomarker expression in triple-negative breast cancer.
    Speiser J; Foreman K; Drinka E; Godellas C; Perez C; Salhadar A; Erşahin Ç; Rajan P
    Int J Surg Pathol; 2012 Apr; 20(2):139-45. PubMed ID: 22084425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological work up of the primary tumor: getting the proper information out of it.
    Viale G
    Breast; 2011 Oct; 20 Suppl 3():S82-6. PubMed ID: 22015299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.